

OASIS NUTRACEUTICALS LIMITED

(Formerly known Sam Leaseco Limited)

(CIN No: L51101MH1980PLC022765)

H-4/5, Everest Building, 9th Floor, Tardeo Road, Mumbai – 400034, (M.H), India.

Tel: 022-23524403. Email: oasisnutra786@gmail.com

BSE / OASIS / 2018-19

Date: November 14, 2018

The Department of Corporate Services,
BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

Scrip ID: SAMLEPU

Scrip Code: 504345

Sub.: Outcome of Board Meeting held today i.e. November 14, 2018 pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (time: from 1:15 PM to 2:00 PM)

Sir / Madam,

The Board of Directors at its meeting held today i.e. Wednesday, November 14, 2018 had inter-alia considered and approved the Un-Audited Financial Results for the Quarter and half year ended September 30, 2018, a copy of the same is enclosed alongwith Limited Review Report;

The above is for your kind information and record. You are requested to acknowledge the receipt.

Thanking you,

Yours faithfully,
For Oasis Nutraceuticals Limited


Rajkishore Maniyar
Managing Director



Encl. as above

OASIS NUTRACEUTICALS LIMITED

(FORMERLY KNOWN AS SAM LEASECO LIMITED)

Regd. Off.: H-4-5, Everest Building, 9th Floor, Tardeo Road, Mumbai - 400034, Maharashtra (CIN: L51101MH1980PLC022765)

Statement of standalone Unaudited Financial Results For the Quarter and Half Year Ended on 30th September, 2018

(Rupees in Lakh Except EPS)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2018 Unaudited	30.06.2018 Unaudited	30.09.2017 Unaudited	30.09.2018 Unaudited	30.09.2017 Unaudited	31.03.2018 Audited
1	Income						
a)	Revenue from Operations	0.00	0.00	0.00	0.00	0.00	474.66
b)	Other Income	10.13	10.13	9.77	20.25	19.45	43.80
	Total Revenue :	10.13	10.13	9.77	20.25	19.45	518.45
2	Expenses						
a)	Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
b)	Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	499.69
c)	Change in Inventories of Stock in Trade	0.00	0.00	0.00	0.00	0.00	0.00
d)	Employees Benefit Expenses	6.00	0.00	0.00	6.00	0.00	0.00
e)	Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00	0.00
f)	Finance Cost	0.00	0.00	0.00	0.00	0.00	0.00
g)	Listing Fees	2.95	0.00	0.00	2.95	2.88	2.88
h)	Other Expenses	2.18	1.18	1.18	3.36	3.79	5.88
	Total Expenses :	11.13	1.18	1.18	12.31	6.67	508.45
3	Total Profit / (Loss) before exceptional tax (1 - 2)	-1.00	8.95	8.59	7.95	12.79	10.00
4	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
5	Net Profit / (Loss) before tax (3 ± 4)	-1.00	8.95	8.59	7.95	12.79	10.00
6	Tax Expense						
	Current Tax	0.00	0.00	0.00	0.00	0.00	2.57
	Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
	Total Tax Expenses :	0.00	0.00	0.00	0.00	0.00	2.57
6	Net Profit / (Loss) for the period from continuing operations (5 - 6)	-1.00	8.95	8.59	7.95	12.79	7.43
7	Other Comprehensive Income						
	Amount of Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
8	Total Comprehensive Profit / (Loss)	-1.00	8.95	8.59	7.95	12.79	7.43
9	Paid up Equity Share Capital (FV Re.1/-)	1020.00	1020.00	1020.00	1020.00	1020.00	1020.00
10	Reserves excluding revaluation reserve as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00	0.00	0.00
11	Earnings per Share (EPS)						
	- Basic EPS (Rs.)	0.00	0.01	0.01	0.01	0.01	0.01
	- Diluted EPS (Rs.)	0.00	0.01	0.01	0.01	0.01	0.01

Notes :

- 1 The above results have been reviewed by the Audit Committee and approved at the meeting of the Board of Directors held on 14th November, 2018 and the statutory auditors of the Company have carried out a Limited Review report for the Quarter and Half Year Ended 30th September, 2018
- 2 The Company is engaged in only one Segment and as such there are no separate reportable segments as per 'IND AS - 108' Operating Segments.
- 3 Provision for income tax will be made at the end of financial year.
- 4 Figures for the Previous periods have been regrouped / rearranged, wherever necessary.

Place : Mumbai
Date : 14.11.2018

Oasis Nutraceuticals Limited

Rajkishore Maniyar
Managing Director

OASIS NUTRACEUTICALS LIMITED

(FORMERLY KNOWN AS SAM LEASECO LIMITED)

Regd. Off.: H-4-5, Everest Building, 9th Floor, Tardeo Road, Mumbai - 400034, Maharashtra (CIN: L51101MH1980PLC022765)


Statement of standalone Unaudited Financial Results For the Quarter and Half Year Ended on 30th September, 2018

(Rupees in Lakh Except EPS)

5 Statement of Assets and Liabilities

	Particulars	As at 30.09.2018 Unaudited	As at 31.03.2018 Audited
A.	ASSETS		
1	Non-current assets		
	Property, plant and equipment	-	-
	Non - Current Financial Assets		
	Non-current Investments	9.22	9.22
	Loans, Non-current	1,056.39	1,036.14
	Other Non-current Financial assets	-	-
	Total Non-current Financial Assets	1,065.61	1,045.36
	Deferred tax assets (net)	0.02	0.02
	Other non-current assets	-	-
	Total Non-current assets	1,065.63	1,045.38
2	Current assets		
	Inventories	2.41	2.41
	Current Financial Assets		
	Current Investments	100.45	100.45
	Trade Receivables, Current	999.32	951.37
	Cash and Bank equivalents	0.87	1.01
	Bank balances other than Cash and Bank equivalents	-	-
	Loans, current	-	-
	Other current financial assets	-	-
	Total current financial assets	1,040.64	1,052.83
	Current Assets (net)	11.11	10.03
	Other Current Assets	-	-
	Total Current assets	1,054.16	1,065.28
	TOTAL - ASSETS	2,119.80	2,110.66
B.	EQUITY AND LIABILITIES		
1	Equity		
	Equity attributable to owners of parent		
	Equity Share Capital	1,020.00	1,020.00
	Other Equity	119.61	111.66
	Total equity attributable to owners of parent	1,139.61	1,131.66
	Non-controlling interests	-	-
	Total Equity	1,139.61	1,131.66
2	Liabilities		
	Non-current Liabilities		
	Non-current Financial Liabilities		
	Borrowings, non-current	41.61	41.61
	Trade payables, non-current	-	-
	Other non-current financial liabilities	-	-
	Total non-current financial liabilities	41.61	41.61
	Provisions, non-current	-	-
	Deferred tax liabilities (net)	-	-
	Deferred government grants, Non-current	-	-
	Other non-current liabilities	92.15	92.15
	Total non-current liabilities	92.15	92.15
	Current Liabilities		
	Current Financial Liabilities		
	Borrowings, current	-	-
	Trade Payables, current	828.26	832.26
	Other current financial liabilities	-	-
	Other current liabilities		
	Provisions, current	12.81	11.27
	Current tax liabilities (net)	5.35	1.71
	Deferred government grants, current	-	-
	Total current liabilities	846.43	845.24
3	Liabilities directly associated with assets in disposal group classified as held for sale	-	-
4	Regulatory deferral account credit balances and related deferred tax liability	-	-
	Total liabilities	-	-
	Total equity and liabilities	2,119.80	2,110.66

Place : Mumbai
Date : 14.11.2018

Oasis Nutraceuticals Limited

Balakrishna Maniyar
Managing Director

Limited Review Report of Oasis Nutraceuticals Limited (Formerly Known as Sam Leaseco Limited) Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

**TO BOARD OF DIRECTORS
Oasis Nutraceuticals Limited**

We have reviewed the accompanying Statement of Unaudited Financial Results of **OASIS NUTRACEUTICALS LIMITED** ("the Company") for the quarter and half year ended 30th September, 2018 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016.

This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016 is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information" Performed by the Independent Auditors of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI

(Listing Obligations and Disclosures Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Singhvi & Sancheti.
Chartered Accountants
FRN:- 110286W



(HM Sancheti)
Partner
M.No.043331

Date: 14.11.2018
Place: Mumbai